| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in Sierra Oncology, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/11/2022 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 07/08/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/08/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/05/2022 |
SC 13G/A
| Vivo Capital IX, LLC reports a 0% stake in Sierra Oncology, Inc. |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/01/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/01/2022 |
8-K
| Quarterly results |
| 07/01/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 06/29/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 06/22/2022 |
8-K
| Other Events Interactive Data |
| 06/01/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 05/06/2022 |
SC 13D/A
| Longitude Capital Partners III, LLC reports a 5.7% stake in SIERRA ONCOLOGY, INC. |
| 05/06/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/06/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/22/2022 |
SC 13G
| Versor Investments LP reports a 5.3% stake in SIERRA ONCOLOGY, INC. |
| 04/13/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 04/13/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Agreement and Plan of Merger, between GlaxoSmithKline plc, Orikum Acquisition Inc., and Sierra Oncology, Inc",
"Form of Support Agreement, by and among GlaxoSmithKline plc, Orikum Acquisition Inc., Sierra Oncology, Inc, and certain securityholders of Sierra Oncology, Inc",
"GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn" |
|
|